Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders

Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized massive parallel sequencing of 54 genes previously associated with MDS/AML pathogenesis. Serial sampling before and during AZA therapy of 38 patie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Polgarova, Kamila, Vargova, Karina, Kulvait, Vojtech, Dusilkova, Nina, Minarik, Lubomir, Zemanova, Zuzana, Pesta, Michal, Jonasova, Anna, Stopka, Tomas
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762372/
https://ncbi.nlm.nih.gov/pubmed/29340104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22957
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items